Full drug dose achieved in prostate trial
In the Phase 1 study SpectraCure is conducting for the treatment of patients with relapse of prostate cancer, the third and final level of the drug dose has now been achieved. The first full-dose patient was treated this week at the Princess Margaret Cancer Centre in Toronto, Canada. The treatment method, called photodynamic therapy (PDT), […]
EU Grant awarded through Vinnova
SpectraCure has been granted a research and development grant linked to EU's major research and innovation Framework Programme, Horizon 2020. The grant is in the Industrial leadership sub-area, and is a so-called SME instrument in Phase 1, a contribution towards small and medium-sized research companies. The grant includes SEK 500 000 in Phase 1, and […]
An additional patient has been treated in Toronto, Canada
Another patient in the SpectraCure Phase 1 study has been treated for relapse of prostate cancer at Princess Margaret Cancer Centre in Toronto, Canada. The treatment went well and the SpectraCure technology worked according to plan. There are a number of patients on the waiting list waiting for treatment. The procedure used SpectraCures IDOSE® technology for […]
Patent for dose control approved in Canada
The Canadian Patent Office has approved a patent for improved dose control for the SpectraCure technology for treatment of prostate cancer with photodynamic therapy (PDT). The patent is part of the SpectraCures patent area for dose control, covering the software IDOSE® which ensures that the correct laser light dose is delivered to the tumour to […]
Communiqué from the Annual General Meeting 2017
At the SpectraCures AGM held in Lund on 23 May 2017, the following decisions were taken. Decisions concerning the adoption of the income statement and balance sheet, etc. The AGM resolved to adopt the income statement and balance sheet for the financial year 2016. The Board of Directors and the Managing director were granted discharge […]
SpectraCure initiates a joint project with German company MedCom GmbH
SpectraCure has initiated a joint project with the German company MedCom GmbH for the improving of SpectraCures technology for the treatment of prostate cancer with photodynamic therapy (PDT). MedCom, based in Darmstadt, is the world leader in image-based control of minimally invasive procedures for diagnostics and treatment. The company delivers technical solutions to several major […]
Patient treatments started in clinical Phase 1 study
The first patient in the SpectraCure Phase 1 study has been treated for prostate cancer at Princess Margaret Cancer Centre in Toronto, Canada. The treatment went well and the patient is doing fine. The SpectraCure IDOSE® Technology for treatment planning and laser light dose delivery to the tumour was used. The treatment method, called Photodynamic […]
Notice of annual general Meeting of SpectraCure AB (publ)
The shareholders of SpectraCure AB (publ), Org.nr 556642-1011 ("the Company") are hereby invited to the annual general meeting on Tuesday 23 May 2017 at. 11.00 at the company's premises, Magistratsvägen 10, 226 43 Lund. Notifications, etc., Shareholders who wish to participate in the annual general meeting must: be entered in the share register maintained by […]
The first day of trading with warrants of series TO2 is estimated at 27 January 2017
The first day of trading in the newly issued shares was 23 January 2017 and the first day of trading of series TO 2 warrants is expected to be Friday, January 27, 2017. After registration of the issue, the number of shares amounts to 56 591 520 and the number of warrants to 26 604 […]
SpectraCure decides on Set-off Issue
The Board of Directors has, on the basis of authorization at the annual general meeting (AGM) on 18 May 2016, decided to issue 2 493 780 units at the same rate as in the recently completed rights issue (0.80 SEK) for compensation equivalent to SEK 1 995 024 to advisors in accordance with contract. The […]
